Overview
Time-restricted eating (TRE) has gained attention as a simple way to improve metabolic health without requiring detailed calorie counting or major changes in food choice. In TRE, all daily food and drink calories are consumed within a fixed window, usually 6 to 10 hours, with fasting outside that window. This trial tested whether TRE is at least as effective as individualized dietetic guidance (IDG) for improving long-term blood sugar control in adults at risk of type 2 diabetes.
The main question was whether TRE could match a more traditional, dietitian-led approach in lowering HbA1c, a blood test that reflects average blood glucose over the previous 2 to 3 months. People with overweight or obesity and a high diabetes risk score were studied because they are more likely to progress to type 2 diabetes and may benefit from early lifestyle intervention.
Why this study matters
Type 2 diabetes is one of the most common chronic diseases worldwide, and prevention is a major public health priority. Lifestyle change is a cornerstone of prevention, but standard dietary counseling can be time-intensive and may not be easily accessible for everyone. TRE is appealing because it is straightforward: instead of focusing on what to eat, it focuses on when to eat.
However, enthusiasm for TRE has outpaced strong comparative evidence. Many studies have been short, small, or lacked an active comparison group. This trial is important because it directly compared TRE with individualized dietetic guidance in a randomized clinical design and followed participants for 12 months.
Study design and participants
This was a two-arm, parallel-group, multicenter randomized non-inferiority clinical trial conducted at two Australian clinical research institutes. Adults at risk of type 2 diabetes were eligible if they had overweight or obesity and a score of 15 or higher on the Australian type 2 diabetes risk assessment tool.
A total of 247 participants were randomized: 124 to TRE and 123 to IDG. The average baseline HbA1c was 40 mmol/mol, or 5.8%, which is in the range often considered prediabetes or high-normal depending on the guideline used. This means the group was at elevated metabolic risk but had not yet developed overt diabetes.
Randomization was done electronically in a 1:1 ratio. The staff who measured outcomes and analyzed data were blinded to treatment allocation, which helps reduce bias. Participants and dietitians could not be blinded because the interventions were behavior-based and obviously different.
The interventions
Participants in the TRE group were asked to eat within a self-selected 9-hour window each day, with the last eating occasion by 19:00 hours. This format was designed to be practical and adaptable to daily life. The key idea was to compress energy intake into a consistent daily eating window, while maintaining usual food choices as much as possible.
Participants in the IDG group received personalized dietetic guidance based on standard nutritional counseling principles. This likely included advice tailored to the individual’s diet, habits, and goals, with attention to energy balance, healthier food choices, and sustainable eating patterns. In practice, this represents the sort of support many people receive from a dietitian in routine care.
Both groups received five personalized telehealth consultations over the first 3 months, totaling 3 hours of contact time. This equalized support is important because it allows the study to test the specific effect of the dietary strategy itself rather than simply the effect of more coaching.
Main and secondary outcomes
The primary outcome was the difference between groups in the change in HbA1c at 4 months. The investigators used a non-inferiority design, meaning the goal was not necessarily to prove TRE was better, but to show that it was not unacceptably worse than individualized dietetic guidance. The prespecified non-inferiority margin was 1.1 mmol/mol, or 0.10% HbA1c.
Secondary outcomes included HbA1c at 12 months and changes in fasting glucose, insulin, insulin resistance assessed by HOMA-IR, and nocturnal glucose area under the curve. Exploratory outcomes included cardiometabolic measures and body mass and composition. Adverse events were monitored for the full 12 months.
Key results at 4 months
At 4 months, TRE met the criterion for non-inferiority compared with IDG for HbA1c. The mean between-group difference was -0.22 mmol/mol, or -0.02%, with a 95% confidence interval from -0.72 to 0.30 mmol/mol. In practical terms, this means TRE performed similarly to individualized dietetic guidance in the short term.
TRE was not superior to IDG, and the p value did not suggest a meaningful difference between the groups. Importantly, the actual changes in HbA1c were very small in both groups. That means even though the statistical comparison was informative, the clinical impact on blood sugar was limited over this time period.
Key results at 12 months
By 12 months, the picture changed. The upper bound of the confidence interval for the between-group difference exceeded the non-inferiority margin, so non-inferiority could no longer be confirmed at this later time point. The mean difference was 0.47 mmol/mol, or 0.05%, with a 95% confidence interval from -0.19 to 1.23 mmol/mol.
This does not mean TRE clearly performed worse than IDG. Rather, the study could no longer confidently say it was not worse by more than the prespecified margin. Again, the absolute differences remained very small and were not clinically meaningful. In other words, there was no strong evidence that either approach produced a major long-term HbA1c benefit in this population.
Other metabolic findings
The abstract reports that secondary and exploratory outcomes included fasting glucose, insulin, HOMA-IR, nocturnal glucose exposure, body weight, body composition, and broader cardiometabolic markers. Although the summary does not provide all numerical details, the overall interpretation is that neither intervention produced large metabolic changes.
This is not surprising. In people who do not yet have diabetes, modest lifestyle changes often lead to modest improvements, especially when baseline HbA1c is already only mildly elevated. A relatively small change in behavior may improve routine or energy intake patterns without dramatically altering blood glucose markers.
Safety and tolerability
Adverse events were minor and similar in both groups. That is reassuring because one concern with fasting-based approaches is whether they may cause headaches, fatigue, irritability, overeating during the eating window, or difficulty maintaining social routines. In this trial, no major safety signal emerged.
That said, people with diabetes, especially those using insulin or medications that can cause hypoglycemia, may need closer supervision before starting time-restricted eating. This study focused on adults at risk of diabetes rather than people already taking glucose-lowering medication, so its results should not be generalized too broadly to all patients with diabetes.
What the findings mean in practice
The main practical takeaway is that TRE may be a reasonable short-term alternative to individualized dietetic guidance when access to a dietitian is limited, or when a person prefers a simpler eating structure. Because TRE is easy to explain and implement, it may help some people start a healthier routine without the burden of complex diet planning.
However, this trial also shows that TRE is not a magic solution. The blood sugar improvements were small, and by 12 months the evidence was not strong enough to confirm non-inferiority using the trial’s strict statistical threshold. That suggests TRE should be viewed as one tool among many, not as a replacement for broader lifestyle support when that support is available.
Strengths and limitations
This study had several strengths. It was randomized, included an active comparator, used blinded outcome assessment, and followed participants for 12 months. The telehealth delivery model also makes the findings relevant to modern clinical care, especially where remote coaching is increasingly common.
There are also limitations. The population was specific: adults with overweight or obesity at elevated diabetes risk in Australia. Results may differ in younger adults, older adults, people with different cultural eating patterns, or patients already diagnosed with type 2 diabetes. The intervention also relied on adherence, and real-world adherence to a fixed eating window may vary over time.
Another important point is that the study was designed as a non-inferiority trial. That means a “not significantly different” result should not be read as proof that the two approaches are identical. It means the researchers tested whether TRE was close enough to standard support to be considered a practical alternative within a predefined tolerance.
Clinical perspective
For clinicians, this trial suggests that discussing meal timing may be a useful entry point for patients who feel overwhelmed by traditional dietary advice. TRE can be especially attractive for people who prefer clear rules and want a simple structure rather than counting calories or changing multiple food habits at once.
For patients, the message is balanced: TRE may help establish consistency and may fit better with daily life, but its effects on blood sugar may be modest. Long-term prevention of type 2 diabetes still depends on a broader package of healthy behaviors, including physical activity, weight management when appropriate, sleep, and sustainable eating habits.
Bottom line
In adults at risk of type 2 diabetes, time-restricted eating was non-inferior to individualized dietetic guidance for HbA1c at 4 months, but this was not sustained at 12 months. The blood sugar changes were small in both groups, and adverse events were minor. TRE may be a practical short-term option when dietetic support is limited or when a person prefers this approach.
Reference
Parr EB, Charrouf R, Hutchison AT, Flint SA, Teong XT, Vincent AD, Bravo-Garcia AP, Siviour Z, Wittert GA, Brennan L, Devlin BL, Hawley JA, Heilbronn LK. Time-restricted eating versus dietetic guidance on glycaemic outcomes in adults at risk of type 2 diabetes: a non-inferiority randomised clinical trial. Diabetologia. 2026-06-06. PMID: 42251202.